Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04190056
Title Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of California, San Francisco

estrogen-receptor positive breast cancer


Pembrolizumab + Tamoxifen

Pembrolizumab + Tamoxifen + Vorinostat

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.